Indivior Pharmaceuticals Inc
INDVNASDAQHealthcare● Active
$37.39
$-0.23(-0.60%)
Market Cap$4.7B
P/E Ratio—
52W High$41
52W Low$13.44
Indivior Pharmaceuticals Inc（INDV）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · INDV · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.21B | $0.00B | ($0.13B) | ($0.04B) | $0.21B |
| Depreciation & Amort. | $0.02B | $0.03B | $0.01B | $0.02B | $0.02B |
| Stock-Based Comp. | $0.03B | $0.02B | $0.02B | $0.02B | $0.01B |
| Change in Working Capital | ($0.26B) | ($0.04B) | ($0.29B) | $0.12B | $0.17B |
| Net Cash from Operations | ($0.03B) | $0.04B | ($0.30B) | ($0.00B) | $0.35B |
| Investing Activities | |||||
| Capital Expenditure | ($0.07B) | ($0.03B) | ($0.05B) | ($0.01B) | ($0.03B) |
| Purchases of Investments | ($0.02B) | ($0.02B) | ($0.04B) | ($0.24B) | $0.00B |
| Sales of Investments | $0.00B | $0.12B | $0.13B | $0.03B | $0.00B |
| Net Cash from Investing | ($0.07B) | $0.07B | ($0.10B) | ($0.22B) | ($0.01B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.01B) | ($0.17B) | ($0.03B) | ($0.09B) | ($0.10B) |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | ($0.02B) | $0.09B | ($0.01B) | ($0.00B) | $0.01B |
| Net Cash from Financing | ($0.03B) | ($0.10B) | ($0.06B) | ($0.10B) | ($0.09B) |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.09B) | $0.01B | ($0.35B) | ($0.01B) | $0.32B |
| FCF Margin %(computed) | -7.51% | 0.59% | -32.30% | -1.00% | 40.33% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Indivior Pharmaceuticals Inc
关于Indivior Pharmaceuticals Inc（INDV）现金流量表
Indivior Pharmaceuticals Inc 2025财年经营活动现金流($0.03B)，自由现金流($0.09B)（FCF利润率-7.51%），资本支出($0.07B)。
常见问题
INDV · 4 问Indivior Pharmaceuticals Inc 2025财年自由现金流($0.09B)，同比down1428.6%。
INDV free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10